Floatz logo

bkt140

T-Acute Lymphoblastic Leukemia

Washington University School of MedicinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the T-Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

bkt140 is also rated in:

pancreatic adenocarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
61 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →